Abstract
Purpose: :
To report the changes in visual acuity at the 5-year follow-up examination in a longitudinal cohort study of birdshot chorioretinopathy.
Methods: :
A single center longitudinal cohort study of 80 subjects with birdshot chorioretinopathy was initiated at Hôpital Cochin, Paris. Subjects were followed prospectively and evaluated for best-corrected visual acuity (BCVA). The BCVA at the baseline and 5-year follow-up examinations were evaluated to determine the magnitude of change in BCVA. BCVA was measured with a decimal scale and for purpose of analysis was converted to logMAR units. Initial and 5-year BCVA were compared using the Wilcoxon signed rank test.
Results: :
At the 5-year follow-up examination 127 eyes of 64 subjects were evaluated. BCVA at baseline for these eyes was median 0.8 (range 1.2 to counting fingers) and mean 0.6. The BCVA at 5 years was median 0.9 (range 1.2 to counting fingers) and mean between 0.5 and 0.6. The mean logMAR score was 0.21 ± 0.36 at baseline and 0.26 ± 0.61 at 5 years. This difference between the baseline and 5-year follow-up BCVA was not statistically significant (p=0.22). Among 120 eyes with a BCVA better than 0.1 at baseline, six (5%) lost two or more lines of vision over 5 years. Of 108 eyes that were tested at the 5-year follow-up that had a BCVA of 0.5 or better at baseline, four (3.7%) had a BCVA of less than 0.5, including two eyes with subretinal neovascular membranes, both of which had hand motion vision. No eye that was 1.0 or better at baseline was worse than 0.5 at 5 years.
Keywords: autoimmune disease • clinical (human) or epidemiologic studies: outcomes/complications • visual acuity